Pan Cancer T is a biotechnology company that develops T‑cell receptor T‑cell therapies to treat solid tumors.
Pan Cancer T has raised $5.8M in total funding. The most recent round was Seed. The last funding was announced in December 2025.
Pan Cancer T's investors include InnovationQuarter, Thuja Capital, Van Herk Ventures, Erasmus MC, Ministry of Economic Affairs (Innovation Credit).
Pan Cancer T is headquartered in Rotterdam, The Netherlands.
Pan Cancer T is a biotechnology company that develops T‑cell receptor T‑cell therapies to treat solid tumors.
Pan Cancer T is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pan Cancer T — Funding & Investors." VCBacked, December 8, 2025, https://www.vcbacked.co/company/pan-cancer-t. Accessed August 14, 2026.
VCBacked. (2025). Pan Cancer T — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/pan-cancer-t
{{cite web |title=Pan Cancer T — Funding & Investors |url=https://www.vcbacked.co/company/pan-cancer-t |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated